Modeling distinct osteosarcoma subtypes in vivo using Cre: Lox and lineage-restricted transgenic shRNA

Bone

Volumn 55, Issue 1, 2013, Pages 166-178

  Mutsaers, Anthony J ^a   Ng, Alvin J M ^a,b   Baker, Emma K ^a,b   Russell, Megan R ^a   Chalk, Alistair M ^a   Wall, Meaghan ^c   Liddicoat, Brain J J ^a,b   Ho, Patricia W M ^a   Slavin, John L ^c   Goradia, Ankita ^a   Martin, T John ^a,b   Purton, Louise E ^a,b   Dickins, Ross A ^d   Walkley, Carl R ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Osteoblastic subtype; Osteosarcoma; P53; ShRNA

Indexed keywords

SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; CRE GENE; FLOW CYTOMETRY; GENE DELETION; GENE SILENCING; GENE TARGETING; IN VIVO STUDY; INTERMETHOD COMPARISON; LONG BONE; LOX GENE; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOSARCOMA; P53 GENE; PREVALENCE; RB1 GENE; TRANSGENIC MOUSE; TRP53 GENE;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MEMBRANE; CHROMOSOMES, MAMMALIAN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRASES; KARYOTYPING; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOSARCOMA; PENETRANCE; PHENOTYPE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSGENES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877594683     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.02.016     Document Type: Article

References (50)

1. Bacci G., Longhi A., Fagioli F., Briccoli A., Versari M., Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27year experience at Rizzoli Institute, Italy. Eur J Cancer 2005, 41:2836-2845.
2. Janeway K.A., Barkauskas D.A., Krailo M.D., Meyers P.A., Schwartz C.L., Ebb D.H., et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer 2012, 118:4597-4605.
3. Ng A.J., Mutsaers A.J., Baker E.K., Walkley C.R. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2012, 2:19.
4. Martin T.J., Ingleton P.M., Underwood J.C., Michelangeli V.P., Hunt N.H., Melick R.A. Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma. Nature 1976, 260:436-438.
5. Molyneux S.D., Di Grappa M.A., Beristain A.G., McKee T.D., Wai D.H., Paderova J., et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest 2010, 120:3310-3325.
6. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., West J.C., et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A 2008, 105:11851-11856.
7. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008, 22:1662-1676.
8. Lin P.P., Pandey M.K., Jin F., Raymond A.K., Akiyama H., Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009, 30:1789-1795.
9. Sellers W.R. A blueprint for advancing genetics-based cancer therapy. Cell 2011, 147:26-31.
10. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 2007, 7:654-658.
11. Li Z., Tognon C.E., Godinho F.J., Yasaitis L., Hock H., Herschkowitz J.I., et al. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 2007, 12:542-558.
12. Premsrirut P.K., Dow L.E., Kim S.Y., Camiolo M., Malone C.D., Miething C., et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011, 145:145-158.
13. Dickins R.A., McJunkin K., Hernando E., Premsrirut P.K., Krizhanovsky V., Burgess D.J., et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 2007, 39:914-921.
14. Zuber J., McJunkin K., Fellmann C., Dow L.E., Taylor M.J., Hannon G.J., et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol 2011, 29:79-83.
15. MacPherson D., Sage J., Crowley D., Trumpp A., Bronson R.T., Jacks T. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol Cell Biol 2003, 23:1044-1053.
16. Rodda S.J., McMahon A.P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006, 133:3231-3244.
17. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
18. Singbrant S., Russell M.R., Jovic T., Liddicoat B., Izon D.J., Purton L.E., et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 2011, 117:5631-5642.
19. Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
20. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
21. Morikawa S., Mabuchi Y., Kubota Y., Nagai Y., Niibe K., Hiratsu E., et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 2009, 206:2483-2496.
22. Brady C.A., Jiang D., Mello S.S., Johnson T.M., Jarvis L.A., Kozak M.M., et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145:571-583.
23. Piccinin S., Tonin E., Sessa S., Demontis S., Rossi S., Pecciarini L., et al. A "twist box" code of p53 inactivation: twist box:p53 interaction promotes p53 degradation. Cancer Cell 2012, 22:404-415.
24. Schroeder M., Mass M.J. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Commun 1997, 235:403-406.
25. Taylor B.S., Barretina J., Maki R.G., Antonescu C.R., Singer S., Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011, 11:541-557.
26. Monroe D.G., McGee-Lawrence M.E., Oursler M.J., Westendorf J.J. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012, 492:1-18.
27. Cleton-Jansen A.M., Anninga J.K., Briaire-de Bruijn I.H., Romeo S., Oosting J., Egeler R.M., et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 2009, 101:1909-1918.
28. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
29. Maes C., Carmeliet G., Schipani E. Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol 2012, 8:358-366.
30. Tamayo P., Scanfeld D., Ebert B.L., Gillette M.A., Roberts C.W., Mesirov J.P. Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci U S A 2007, 104:5959-5964.
31. Henderson S.R., Guiliano D., Presneau N., McLean S., Frow R., Vujovic S., et al. A molecular map of mesenchymal tumors. Genome Biol 2005, 6:R76.
32. Rubin B.P., Nishijo K., Chen H.I., Yi X., Schuetze D.P., Pal R., et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011, 19:177-191.
33. Nakayama R., Nemoto T., Takahashi H., Ohta T., Kawai A., Seki K., et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 2007, 20:749-759.
34. Engin F., Bertin T., Ma O., Jiang M.M., Wang L., Sutton R.E., et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009, 18:1464-1470.
35. Ma O., Cai W.W., Zender L., Dayaram T., Shen J., Herron A.J., et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 2009, 69:2559-2567.
36. Haldar M., Hancock J.D., Coffin C.M., Lessnick S.L., Capecchi M.R. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007, 11:375-388.
37. Wang X., Kua H.Y., Hu Y., Guo K., Zeng Q., Wu Q., et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 2006, 172:115-125.
38. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
39. Ellwood-Yen K., Keilhack H., Kunii K., Dolinski B., Connor Y., Hu K., et al. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res 2011, 71:3052-3065.
40. Thurisch B., Liang S.Y., Sarioglu N., Schomburg L., Bungert J., Dame C. Transgenic mice expressing small interfering RNA against Gata4 point to a crucial role of Gata4 in the heart and gonads. J Mol Endocrinol 2009, 43:157-169.
41. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010, 42:454-458.
42. Carracedo A., Alimonti A., Pandolfi P.P. PTEN level in tumor suppression: how much is too little?. Cancer Res 2011, 71:629-633.
43. Bayani J., Zielenska M., Pandita A., Al-Romaih K., Karaskova J., Harrison K., et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 2003, 36:7-16.
44. Kuijjer M.L., Rydbeck H., Kresse S.H., Buddingh E.P., Lid A.B., Roelofs H., et al. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer 2012, 51:696-706.
45. Daino K., Ugolin N., Altmeyer-Morel S., Guilly M.N., Chevillard S. Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiation-induced tumorigenesis of bone. Int J Cancer 2009, 125:612-620.
46. Friedman M.S., Oyserman S.M., Hankenson K.D. Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. J Biol Chem 2009, 284:14117-14125.
47. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999, 4:199-207.
48. Shimizu T., Ishikawa T., Sugihara E., Kuninaka S., Miyamoto T., Mabuchi Y., et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010, 29:5687-5699.
49. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
50. Mogi M., Kondo A. The presence of TRAIL-OPG complex in human osteosarcoma and human salivary gland adenocarcinoma. J Immunoassay Immunochem 2011, 32:70-78.